Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus
Open Access
- 15 June 2007
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 81 (12), 6379-6388
- https://doi.org/10.1128/jvi.00105-07
Abstract
Ebola virus causes outbreaks of severe viral hemorrhagic fever with high mortality in humans. The virus is highly contagious and can be transmitted by contact and by the aerosol route. These features make Ebola virus a potential weapon for bioterrorism and biological warfare. Therefore, a vaccine that induces both systemic and local immune responses in the respiratory tract would be highly beneficial. We evaluated a common pediatric respiratory pathogen, human parainfluenza virus type 3 (HPIV3), as a vaccine vector against Ebola virus. HPIV3 recombinants expressing the Ebola virus (Zaire species) surface glycoprotein (GP) alone or in combination with the nucleocapsid protein NP or with the cytokine adjuvant granulocyte-macrophage colony-stimulating factor were administered by the respiratory route to rhesus monkeys—in which HPIV3 infection is mild and asymptomatic—and were evaluated for immunogenicity and protective efficacy against a highly lethal intraperitoneal challenge with Ebola virus. A single immunization with any construct expressing GP was moderately immunogenic against Ebola virus and protected 88% of the animals against severe hemorrhagic fever and death caused by Ebola virus. Two doses were highly immunogenic, and all of the animals survived challenge and were free of signs of disease and of detectable Ebola virus challenge virus. These data illustrate the feasibility of immunization via the respiratory tract against the hemorrhagic fever caused by Ebola virus. To our knowledge, this is the first study in which topical immunization through respiratory tract achieved prevention of a viral hemorrhagic fever infection in a primate model.Keywords
This publication has 50 references indexed in Scilit:
- The ERK Mitogen-Activated Protein Kinase Pathway Contributes to Ebola Virus Glycoprotein-Induced CytotoxicityJournal of Virology, 2007
- Nonsegmented Negative-Strand Viruses as Vaccine VectorsJournal of Virology, 2006
- A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical TrialClinical and Vaccine Immunology, 2006
- Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPsPLoS Medicine, 2006
- Recombinant Newcastle Disease Virus Expressing a Foreign Viral Antigen Is Attenuated and Highly Immunogenic in PrimatesJournal of Virology, 2005
- Infection of Ciliated Cells by Human Parainfluenza Virus Type 3 in an In Vitro Model of Human Airway EpitheliumJournal of Virology, 2005
- Analysis of Human Peripheral Blood Samples from Fatal and Nonfatal Cases of Ebola (Sudan) Hemorrhagic Fever: Cellular Responses, Virus Load, and Nitric Oxide LevelsJournal of Virology, 2004
- Pathogenesis of Ebola Hemorrhagic Fever in Primate ModelsThe American Journal of Pathology, 2003
- Ebola virus: from discovery to vaccineNature Reviews Immunology, 2003
- Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs against Infection with Lassa and Ebola VirusesJournal of Virology, 2001